CEL-SCI Launches Global Confirmatory Registration Study of Multikine® for Newly Diagnosed Head and Neck Cancer
CEL-SCI Corporation has announced the initiation of its global Confirmatory Registration Study evaluating Multikine® (Leukocyte Interleukin, Injection) as a neoadjuvant immunotherapy for patients with newly diagnosed, previously untreated, resectable, locally advanced head and neck cancer. The study represents a significant milestone in the company’s clinical development strategy and is intended to support future regulatory submissions aimed at bringing Multikine to patients worldwide.
The multinational clinical trial will be conducted across leading medical centers in the United States, Europe, Asia, and South America, reflecting CEL-SCI’s global approach to advancing its investigational immunotherapy. The study is designed to confirm the encouraging survival outcomes observed in the company’s previously completed Phase 3 trial while focusing on a carefully selected patient population that demonstrated the greatest clinical benefit from treatment.
As part of the international collaboration, Orient EuroPharma, CEL-SCI’s strategic partner in Taiwan, will oversee and finance patient enrollment within its territory, further strengthening the global execution of the study.
Building on Positive Phase 3 Results
The newly launched registration study is founded on results from CEL-SCI’s completed randomized Phase 3 trial, which enrolled 928 patients with locally advanced head and neck cancer. Detailed analyses of that study identified a subgroup of patients who experienced particularly strong clinical benefits following treatment with Multikine prior to surgery and standard therapy.
Rather than enrolling a broad patient population, the confirmatory study has been specifically designed to evaluate the subgroup that demonstrated the most meaningful improvements in survival during the earlier trial.
The study will enroll approximately 212 patients diagnosed with previously untreated, resectable, locally advanced squamous cell carcinoma of the head and neck whose tumors exhibit low or absent PD-L1 expression and who have no clinical lymph node involvement at the time of enrollment.
By concentrating on this well-defined patient population, investigators aim to maximize the probability of reproducing the favorable outcomes previously observed while conducting a more efficient clinical study.
Optimized Trial Design
According to CEL-SCI, the confirmatory registration study has been statistically optimized to provide approximately 97% statistical power for detecting the survival benefit observed in the earlier Phase 3 trial.
The statistical design is based on an anticipated hazard ratio of 0.34 for overall survival, reflecting the magnitude of benefit previously demonstrated in this subgroup of patients.
Because the selected population has already shown a strong therapeutic response, the company believes a substantially smaller study can generate robust evidence while reducing enrollment requirements and accelerating overall development timelines.
The streamlined design allows researchers to focus resources on the patients most likely to benefit while maintaining rigorous scientific standards expected for a registration-enabling trial.
Evaluating Multikine as Neoadjuvant Immunotherapy
Multikine is being developed as a neoadjuvant immunotherapy, meaning it is administered before surgery and before patients receive conventional treatment.
Unlike many immunotherapies that are introduced after surgery or during advanced stages of disease, Multikine is intended to stimulate the patient’s immune system immediately following diagnosis, when immune function may still be relatively intact.
The investigational therapy is administered during the short interval between diagnosis and surgical removal of the tumor.
The underlying scientific rationale is that early activation of the immune response may help the body recognize and attack cancer cells before surgery, potentially reducing tumor burden and improving long-term clinical outcomes.
Following completion of Multikine therapy, patients proceed to standard treatment, including surgery and any additional therapies deemed appropriate according to clinical guidelines.
Addressing an Important Patient Population
Head and neck squamous cell carcinoma remains one of the most challenging cancers to treat despite advances in surgery, radiation therapy, chemotherapy, and immunotherapy.
While checkpoint inhibitors targeting the PD-1/PD-L1 pathway have improved outcomes for many patients with advanced disease, individuals whose tumors express little or no PD-L1 often derive less benefit from these treatments.
The current confirmatory study specifically focuses on patients with low or zero PD-L1 expression, representing a population with significant unmet medical need.
CEL-SCI believes this targeted approach may provide a valuable therapeutic option for patients who currently have fewer effective immunotherapy alternatives.
Survival Benefits Observed in Previous Research
The design of the new registration study is supported by notable findings from the completed Phase 3 trial.
Within the selected subgroup of patients meeting the same disease characteristics as those planned for enrollment in the confirmatory study, investigators observed a substantial improvement in long-term survival among patients receiving Multikine prior to standard treatment.
According to CEL-SCI, patients treated with a three-week course of Multikine before surgery achieved a five-year overall survival rate of 73%, compared with 45% among patients receiving standard treatment alone.
These findings suggested a significant reduction in the risk of death and provided the primary scientific rationale for launching the confirmatory registration study.
The company believes reproducing these results in an independent trial could provide compelling evidence supporting future regulatory approval.
Early Tumor Responses Prior to Surgery
In addition to improvements in long-term survival, Multikine demonstrated encouraging effects before surgery during the previous Phase 3 study.
Researchers reported rapid tumor responses following the three-week treatment period, including complete pathological responses in certain patients before surgical intervention.
Within the target patient population:
- The pre-surgical objective response rate reached 13% among Multikine-treated patients.
- No objective responses were observed in patients receiving standard therapy alone.
Investigators also observed meaningful tumor downstaging before surgery.
Approximately 35% of patients receiving Multikine experienced tumor downstaging compared with 13% in the control group.
These findings suggest that Multikine may begin exerting biological activity within only a few weeks of treatment.
Potential Role of Early Endpoints
One important aspect of the confirmatory study involves evaluating early treatment responses as potential regulatory endpoints.
CEL-SCI believes the rapid pre-surgical tumor responses observed during the earlier Phase 3 study may serve as highly informative indicators of long-term patient outcomes.
According to the company, these early objective responses appeared to correlate closely with overall survival, suggesting they may function as predictive biomarkers for long-term benefit.
As a result, CEL-SCI plans to explore the use of these early clinical endpoints in support of potential accelerated or conditional regulatory approval applications in multiple regions.
Such regulatory pathways may allow promising therapies addressing significant unmet medical needs to become available earlier while long-term survival data continue to mature.
Continued Overall Survival Monitoring
Although early tumor responses are expected to play an important role in the development strategy, overall survival remains the primary endpoint for confirming clinical benefit.
Patients enrolled in the study will continue to be followed after treatment, with investigators conducting blinded assessments until the required number of survival events has been reached for final statistical analysis.
This approach allows the company to evaluate both early biological activity and long-term clinical outcomes within the same registration program.
Maintaining blinded follow-up is intended to preserve the scientific integrity of the trial while generating comprehensive evidence supporting the therapy’s effectiveness.
Global Collaboration Supports Development
The multinational nature of the confirmatory study is expected to facilitate broad patient enrollment while ensuring participation from diverse healthcare systems and clinical investigators.
Clinical sites throughout North America, Europe, Asia, and South America will contribute to the study, enhancing the generalizability of the findings across different patient populations.
Orient EuroPharma’s responsibility for enrollment activities in Taiwan further strengthens the program by leveraging regional expertise and established clinical infrastructure.
The collaboration reflects CEL-SCI’s strategy of building international partnerships to accelerate the development and potential commercialization of Multikine.
Company Perspective
Geert Kersten, Chief Executive Officer of CEL-SCI, described the launch of the confirmatory registration study as a defining milestone in the company’s effort to establish Multikine as a potential new standard of care for patients with newly diagnosed head and neck cancer exhibiting low or absent PD-L1 expression.
He noted that the study has been carefully designed around the patient population that demonstrated statistically significant improvements in overall survival, quality of life, and safety during the previous Phase 3 trial.
Kersten emphasized that the combination of targeted patient selection, robust statistical design, and global participation provides a strong opportunity to validate the earlier findings and advance Multikine toward regulatory approval.
The initiation of the Confirmatory Registration Study marks the next major step in CEL-SCI’s long-term development program for Multikine. By focusing on the patient subgroup that experienced the greatest benefit in earlier research, the company aims to generate high-quality evidence supporting the therapy’s role as a neoadjuvant immunotherapy for locally advanced head and neck cancer.
If the study successfully confirms the previously observed improvements in survival and early tumor response, Multikine could represent an important advancement for patients with limited treatment options, particularly those with low or no PD-L1 expression. Combined with the potential use of early clinical endpoints for accelerated regulatory pathways, the trial positions CEL-SCI to pursue broader global approval while continuing to evaluate long-term survival outcomes through rigorous follow-up.
About Head and Neck Cancer
Head and neck cancer remains one of the world’s most challenging oncology indications, with approximately 900,000 new diagnoses annually. Despite modern iterations of surgery and chemoradiation, long-term survival outcomes have stalled, highlighting a critical global need for non-toxic neoadjuvant immunotherapies that directly improve survival.
About Multikine
Multikine (Leukocyte Interleukin, Injection) is a novel, patented investigational cancer immunotherapy designed to be administered immediately following diagnosis, prior to surgery, radiation, or chemotherapy. By treating patients before any other treatment, while their immune systems are still intact, Multikine aims to stimulate a robust anti-tumor immune response before the immune system is compromised by conventional treatments. Multikine has been administered to over 740 patients across its clinical development program and has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the neoadjuvant therapy of squamous cell carcinoma of the head and neck.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on activating the immune system to fight cancer at the earliest stage of clinical intervention. The Company maintains primary operations in Vienna, Virginia, and manufacturing/operations near Baltimore, Maryland.